The Evolving Landscape in the Management & Treatment of Multiple Sclerosis - Payer Considerations for Providing Support to People with MS and Their Care Partners

Learn About:

• Current and emerging therapies and how they impact disease control
• Maintaining continuity of care through minimizing treatment disruptions caused by changes in formulary status of a drug
• How to reduce barriers between providers and payers

Expert Faculty Presenters:

Dana McCormick, RPh, FAMCP Director of Pharmacy Blue Cross Blue Shield of Texas Click here for biography Jacqueline A. Nicholas, MD, MPH System Chief Neuroimmunology & Multiple Sclerosis OhioHealth Multiple Sclerosis Center Click here for biography Melissa Barnhill, MPH Director of Mission Delivery and Community Engagement Multiple Sclerosis Association of America (MSAA) Click here for biography

Target Audience
The primary target audience for this initiative consists of medical directors, pharmacy directors, clinical pharmacists, specialty pharmacists, registered nurses, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.

Statement of Need/Program Overview
Despite the availability of more than a dozen disease modifying therapies (DMTs), health care resource utilization associated with MS is significant and continues to rise. In this webcast, we will look at ways to develop and implement access and reimbursement policies that lower barriers to timely and patient-appropriate care.

Educational Objectives
After completing this activity, the participant should be better able to:

• Assess how current and emerging therapies impact disease control and how they fit into the MS treatment algorithm.
• Employ strategies to enhance multidisciplinary MS care management.
• Evaluate improvements to continuity of care through minimizing treatment disruptions caused by changes in formulary status of a drug.
• Illustrate how to reduce barriers between providers and payers by integrating data generated by specialty pharmacy partners into MS treatment decision making.

Accreditation Information

Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER), the Multiple Sclerosis Association of America (MSAA), and Impact Education, LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional Continuing Education (IPCE)
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physician Continuing Medical Education
Medical Education Resources designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Medical Education Resources designates this continuing education activity for 1.5 contact hour (0.15 CEU) of the Accreditation Council for Pharmacy Education.

UAN: JA0003680-0000-23-140-L01-P
Type of Activity: Knowledge

Please note: Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Disclosure of Relevant Financial Relationships
It is the policy of Medical Education Resources, Inc. to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, Medical Education Resources, Inc. identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Medical Education Resources, Inc. to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

The MER planners and managers have nothing to disclose.
The MSAA planners and managers have nothing to disclose.
The Impact Education, LLC® planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.